Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bacitracin + neomycin + polymyxin B + pramoxine is a topical combination drug used to prevent infection and relieve pain in minor skin injuries such as cuts, scrapes, and burns. It is sold over-the-counter, primarily under the brand name **Neosporin Plus Pain Relief**. The combination contains three antibiotics (bacitracin, neomycin, polymyxin B), which together provide broad-spectrum antibacterial activity against Gram-positive and Gram-negative bacteria. Bacitracin inhibits bacterial cell wall synthesis; neomycin binds to bacterial ribosomes, inhibiting protein synthesis; polymyxin B disrupts bacterial cell membranes. Pramoxine is a local anesthetic that relieves pain by blocking nerve signal conduction in the skin[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bacitracin + neomycin + polymyxin B + pramoxine.